دورية أكاديمية
Comprehensive analysis of SARS-CoV-2 antibody dynamics in New Zealand.
| العنوان: | Comprehensive analysis of SARS-CoV-2 antibody dynamics in New Zealand. |
|---|---|
| المؤلفون: | Whitcombe AL; Faculty of Medical and Health Sciences University of Auckland Auckland New Zealand.; Maurice Wilkins Centre University of Auckland Auckland New Zealand., McGregor R; Faculty of Medical and Health Sciences University of Auckland Auckland New Zealand.; Maurice Wilkins Centre University of Auckland Auckland New Zealand., Craigie A; Southern Community Laboratories Dunedin New Zealand., James A; Te Punaha Matatini and School of Mathematics and Statistics University of Canterbury Christchurch New Zealand., Charlewood R; New Zealand Blood Service Auckland New Zealand., Lorenz N; Faculty of Medical and Health Sciences University of Auckland Auckland New Zealand.; Maurice Wilkins Centre University of Auckland Auckland New Zealand., Dickson JM; School of Biological Sciences University of Auckland Auckland New Zealand., Sheen CR; Protein Science and Engineering Callaghan Innovation Christchurch New Zealand., Koch B; Protein Science and Engineering Callaghan Innovation Christchurch New Zealand., Fox-Lewis S; LabPLUS Auckland City Hospital Auckland New Zealand., McAuliffe G; LabPLUS Auckland City Hospital Auckland New Zealand., Roberts SA; Maurice Wilkins Centre University of Auckland Auckland New Zealand.; LabPLUS Auckland City Hospital Auckland New Zealand., Morpeth SC; Middlemore Hospital Auckland New Zealand., Taylor S; Middlemore Hospital Auckland New Zealand., Webb RH; Faculty of Medical and Health Sciences University of Auckland Auckland New Zealand.; Maurice Wilkins Centre University of Auckland Auckland New Zealand.; Starship Children's Hospital and Kidz First Children's Hospital Auckland New Zealand., Jack S; Public Health South Southern District Health Board Dunedin New Zealand., Upton A; Southern Community Laboratories Dunedin New Zealand., Ussher JE; Maurice Wilkins Centre University of Auckland Auckland New Zealand.; Southern Community Laboratories Dunedin New Zealand.; Department of Microbiology and Immunology University of Otago Dunedin New Zealand., Moreland NJ; Faculty of Medical and Health Sciences University of Auckland Auckland New Zealand.; Maurice Wilkins Centre University of Auckland Auckland New Zealand. |
| المصدر: | Clinical & translational immunology [Clin Transl Immunology] 2021 Mar 14; Vol. 10 (3), pp. e1261. Date of Electronic Publication: 2021 Mar 14 (Print Publication: 2021). |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: John Wiley & Sons Australia, Ltd. on behalf of Australasian Society for Immunology Inc Country of Publication: Australia NLM ID: 101638268 Publication Model: eCollection Cited Medium: Print ISSN: 2050-0068 (Print) Linking ISSN: 20500068 NLM ISO Abbreviation: Clin Transl Immunology Subsets: PubMed not MEDLINE |
| أسماء مطبوعة: | Publication: 2018- : [Milton, Queensland] : John Wiley & Sons Australia, Ltd. on behalf of Australasian Society for Immunology Inc. Original Publication: [London] : Nature Publishing Group, 2012- |
| مستخلص: | Objectives: Circulating antibodies are important markers of previous infection and immunity. Questions remain with respect to the durability and functionality of SARS-CoV-2 antibodies. This study explored antibody responses in recovered COVID-19 patients in a setting where the probability of re-exposure is effectively nil, owing to New Zealand's successful elimination strategy. Methods: A triplex bead-based assay that detects antibody isotype (IgG, IgM and IgA) and subclass (IgG1, IgG2, IgG3 and IgG4) responses against Nucleocapsid (N) protein, the receptor binding domain (RBD) and Spike (S) protein of SARS-CoV-2 was developed. After establishing baseline levels with pre-pandemic control sera ( n = 113), samples from PCR-confirmed COVID-19 patients with mild-moderate disease ( n = 189) collected up to 8 months post-infection were examined. The relationship between antigen-specific antibodies and neutralising antibodies (NAbs) was explored with a surrogate neutralisation assay that quantifies inhibition of the RBD/hACE-2 interaction. Results: While most individuals had broad isotype and subclass responses to each antigen shortly after infection, only RBD and S protein IgG, as well as NAbs, were relatively stable over the study period, with 99%, 96% and 90% of samples, respectively, having responses over baseline 4-8 months post-infection. Anti-RBD antibodies were strongly correlated with NAbs at all time points (Pearson's r ≥ 0.87), and feasibility of using finger prick sampling to accurately measure anti-RBD IgG was demonstrated. Conclusion: Antibodies to SARS-CoV-2 persist for up to 8 months following mild-to-moderate infection. This robust response can be attributed to the initial exposure without immune boosting given the lack of community transmission in our setting. Competing Interests: The authors declare no conflict of interest. (© 2021 The Authors. Clinical & Translational Immunology published by John Wiley & Sons Australia, Ltd on behalf of Australian and New Zealand Society for Immunology, Inc.) |
| References: | Pathology. 2021 Aug;53(5):645-651. (PMID: 34119335) J Clin Microbiol. 2020 Oct 21;58(11):. (PMID: 32826322) Immunology. 2018 Mar;153(3):279-289. (PMID: 29139548) Immunity. 2020 Nov 17;53(5):925-933.e4. (PMID: 33129373) Sci Immunol. 2020 Dec 7;5(54):. (PMID: 33288645) Nat Med. 2021 Jan;27(1):5-6. (PMID: 33257892) Science. 2020 Dec 4;370(6521):1227-1230. (PMID: 33115920) Cell Rep Med. 2020 Oct 20;1(7):100126. (PMID: 33015650) Science. 2020 Aug 14;369(6505):806-811. (PMID: 32434945) Sci Immunol. 2020 Oct 8;5(52):. (PMID: 33033172) Lancet Public Health. 2020 Nov;5(11):e612-e623. (PMID: 33065023) Immunity. 2020 Sep 15;53(3):524-532.e4. (PMID: 32783920) N Engl J Med. 2021 Feb 11;384(6):533-540. (PMID: 33369366) J Infect Dis. 2020 Sep 14;222(8):1280-1288. (PMID: 32761124) Eur J Immunol. 2020 Dec;50(12):2025-2040. (PMID: 33084029) Nat Biotechnol. 2020 Sep;38(9):1073-1078. (PMID: 32704169) J Infect Dis. 2021 Jan 4;223(1):56-61. (PMID: 33128369) Front Med. 2020 Dec;14(6):746-751. (PMID: 33017040) Nat Commun. 2021 Jan 4;12(1):113. (PMID: 33397956) N Engl J Med. 2020 Aug 20;383(8):e56. (PMID: 32767891) J Immunol. 2020 Dec 15;205(12):3491-3499. (PMID: 33127820) PeerJ. 2020 Sep 03;8:e9863. (PMID: 32953275) Science. 2021 Feb 5;371(6529):. (PMID: 33408181) Nat Rev Immunol. 2020 Nov;20(11):709-713. (PMID: 33024281) Nat Commun. 2020 Sep 17;11(1):4704. (PMID: 32943637) Cell. 2020 Nov 12;183(4):1024-1042.e21. (PMID: 32991844) N Engl J Med. 2020 Sep 10;383(11):1085-1087. (PMID: 32706954) J Infect. 2020 Jul;81(1):e80-e81. (PMID: 32283140) |
| فهرسة مساهمة: | Keywords: COVID‐19; SARS‐CoV‐2; Spike protein; immunokinetics; neutralising antibodies |
| تواريخ الأحداث: | Date Created: 20210322 Latest Revision: 20240331 |
| رمز التحديث: | 20240331 |
| مُعرف محوري في PubMed: | PMC7955949 |
| DOI: | 10.1002/cti2.1261 |
| PMID: | 33747511 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 2050-0068 |
|---|---|
| DOI: | 10.1002/cti2.1261 |